1Lars Wallentin MD, Ph D, Richard C, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med, 2009, 361(11): 1045-1057.
2Jemberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with elopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J, 2006, 27(10): 1166-1173.
3Wallentin L, Varenhorst C, James S, et al. Pasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J, 2008, 29(1):21-30.
4Kuliczkkowski W, Witkowski A, Polonski L, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of-the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Plish CardiacSociety, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J, 2009, 30(4):426-435.
5Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol, 2007, 50(19):1852-1856.
6Montalescot G, Lapostolle F, Silvain J, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med, 2014, 371(11):1016-1027.
